Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion, at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of diabetes, fueled by an increasing geriatric population. This demographic trend, coupled with the underdiagnosis of the condition, presents both opportunities and challenges for market participants. The large, untapped population of undiagnosed individuals represents a significant market opportunity for innovative diagnostic solutions. However, the low diagnosis rate also poses a challenge, as untreated diabetes can lead to severe health complications and increased healthcare costs. The geriatric population, with its higher susceptibility to diabetes, further exacerbates this challenge.
To capitalize on the market opportunities and navigate these challenges effectively, companies must focus on developing innovative diagnostic tools and effective patient education programs. By addressing the unmet needs in diabetes diagnosis and management, market participants can differentiate themselves and capture a larger share of this growing market.

What will be the Size of the Type 2 Diabetes Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by advancements in diabetes management, public health, and weight management. Pancreatic beta-cell destruction and the subsequent need for insulin therapy remain at the forefront of market dynamics. Diabetes burden is a significant concern, with diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy posing significant health risks. SGLT2 inhibitors have emerged as a promising treatment option, addressing both glycemic control and cardiovascular disease. Healthcare access and access to care are crucial factors shaping the market. Global health initiatives and healthcare costs are influencing the development of diabetes technology, including insulin delivery devices, glucose sensors, and remote monitoring.

Precision medicine, data analytics, and machine learning are transforming diabetes education and patient engagement. Lifestyle modifications, such as dietary changes and physical activity, remain essential components of diabetes management. Insulin resistance, insulin therapy, and HbA1c testing continue to be key areas of focus in the medical device industry. Ongoing research in areas like Genetic Testing, Stem Cell Therapy, and primary care physician engagement is further shaping the market. Health disparities, early detection, and glycemic control are critical public health concerns. Diabetes prevention and healthcare provider collaboration are essential to improving health outcomes. The market is continually unfolding, with ongoing drug development, clinical trials, and advancements in diabetes technology driving innovation.

How is this Type 2 Diabetes Industry segmented?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

.

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a complex condition characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to elevated blood glucose levels. Metabolic syndrome, an autoimmune disease, and a precursor to type 2 diabetes, affects millions worldwide. The medical device industry is responding with innovative solutions, such as artificial pancreas systems and insulin delivery devices, to improve glycemic control and enhance quality of life. Artificial intelligence and machine learning are revolutionizing diabetes management by facilitating early detection, personalized treatment plans, and remote monitoring. Diabetes burden is significant, with complications including diabetic foot ulcers, diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy.

Prevention and management involve lifestyle modifications, such as dietary changes and physical activity, as well as pharmacological interventions, including oral antidiabetic medications, insulin therapy, and newer classes like GLP-1 receptor a

The number of diabetics worldwide in 2024 was almost *** million. That number is expected to grow until at least the year 2050. The projected number of diabetics is expected to reach around *** million by that time. With an increased number of diabetics, the prevalence of diabetes is also projected to increase to around ** percent by 2050. Diabetes prevalence globally Diabetes is a chronic disease that affects the production and use of insulin in the body which affects blood glucose. Diabetes comes in two types, type 1 and type 2, which require different types of medical treatments. Globally, China, followed by India, has the largest number of diabetics as of 2024. Despite having the highest number of diabetics, China is not among the countries with the highest prevalence. Pakistan, followed by the Marshall Islands, had the highest prevalence of diabetics worldwide as of 2024. Diabetes pharmaceuticals Treatment for diabetes includes insulin, a hormone that regulates blood glucose, and pills to help regulate the effectiveness of insulin. Treatment depends on the type of diabetes. Danish drug manufacturer Novo Nordisk is one of the leading diabetes care companies in the world. In 2024, Novo Nordisk generated around *** billion kroner in revenue from its diabetes care segment.

BackgroundPotentially avoidable hospital admissions (PAHs) due to type 2 diabetes mellitus (T2DM) occur more frequently in Germany than in the rest of Europe. Emergency departments (EDs) play an important role in understanding cross-sectoral health care utilisation resulting in inpatient admissions. Segmenting T2DM patients in homogenous groups according to their health care utilisation may help to understand the population’s needs and to allocate limited resources. The aim of this study was to describe ED use and subsequent inpatient admissions among T2DM patients, and to segment the study population into homogenous subgroups based on disease stage, health care utilisation and process quality of outpatient care prior to an ED visit.MethodsThis study was conducted as part of the INDEED project, comprising data on 56,821 ED visits in 2016 attributable to 40,561 patients with T2DM from 13 German EDs, as well as statutory health insurance claims data from 2014 to 2016 retrospectively linked per patient. Descriptive analyses included patient characteristics, ED admission diagnoses and discharge diagnoses in the case of inpatient admission of T2DM patients to the ED. Latent class analysis was conducted to identify different subgroups of T2DM patients based on disease stage, number of physician contacts and medical examinations prior to the ED visit.ResultsAlmost half of the study population had severe comorbidities (44.3%). In addition to T2DM, multiple cardiovascular diagnoses were among the most frequently documented admission and discharge diagnoses. The proportion of hospitalised ED visits for T2DM patients was higher (59%) than that for the INDEED population (42.8%). We identified three latent classes that were characterised as “early disease stage and high utilisation” (36.5% of the study population), “progressing disease stage and low utilisation” (26.1%) and “progressed disease stage and high utilisation” (37.4%).ConclusionA substantial share of T2DM patients had not received disease monitoring according to guideline recommendations prior to ED presentation. Improving guideline-adherence in the outpatient sector could help reduce potentially avoidable ED visits. Effective interventions that aim at improving continuity and quality of care as well as reducing the share of PAH need to be identified and evaluated per identified class.

Snapshot img

Diabetes Management Devices Market Size 2024-2028

The diabetes management devices market size is forecast to increase by USD 13.98 bn at a CAGR of 7.68% between 2023 and 2028.

The market is witnessing significant growth due to the rising global burden of diabetes and the increasing focus on advanced technologies such as artificial pancreas systems. These systems utilize insulin pumps and continuous glucose monitoring sensors to automatically adjust insulin delivery based on real-time glucose levels. Additionally, the integration of artificial intelligence and data analytics in diabetes management devices is revolutionizing the industry, enabling remote patient monitoring and personalized treatment plans. Other trends include the development of insulin pens with advanced features and the adoption of spectroscopy technology for non-invasive blood glucose monitoring. However, the prohibitive cost of diabetes care devices remains a major challenge for market growth.Overall, the market is expected to experience robust growth In the coming years, driven by technological advancements and the increasing prevalence of diabetes.

What will be the Size of the Diabetes Management Devices Market during the Forecast Period?

Request Free SampleThe market encompasses a range of technologies designed to assist individuals in managing their diabetes, including insulin delivery devices, mobile health applications, and disease management tools. With the global diabetic population projected to reach over 592 million by 2035, driven by factors such as obesity rates, smoking, and high cholesterol levels, the market for diabetes care devices is experiencing significant growth. Hospitals and specialty clinics are increasingly adopting minimally invasive devices, such as diabetes lancet devices and diabetes tracker devices, to improve patient care and outcomes. Type 1 diabetes, an autoimmune disease characterized by insulin deficiency, and Type 2 diabetes, often associated with insulin resistance, both require ongoing management to prevent complications, including kidney failure, gangrene, and lower limb amputation.Insulin delivery devices, including insulin pens and blood glucose level monitoring systems, are essential tools in managing both types of diabetes. The market for diabetes management devices is expected to continue expanding as technology advances and the global population ages.

How is this Diabetes Management Devices Industry segmented and which is the largest segment?

The diabetes management devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ProductBlood glucose monitoring devicesInsulin delivery systemsDistribution ChannelOfflineOnlineGeographyNorth AmericaUSEuropeGermanyUKFranceAsiaChinaRest of World (ROW)

By Product Insights

The blood glucose monitoring devices segment is estimated to witness significant growth during the forecast period. Diabetes management devices play a crucial role in monitoring and managing blood glucose levels for individuals with diabetes. These devices include a range of products such as insulin delivery systems, continuous monitoring systems, and glucose monitoring devices. Insulin delivery devices, including insulin pumps and pens, facilitate precise insulin administration. Continuous monitoring systems, such as continuous glucose monitoring systems (CGMs) and Mobi insulin pumps, provide real-time glucose level data through wireless transmission and dedicated apps. Glucowear, a continuous glucose monitoring system, offers non-invasive transdermal sensors and spectroscopy technology. Hospital pharmacies, retail pharmacies, and online pharmacies stock these diabetes care devices. The increasing prevalence of diabetes among the obese, elderly population, and those with conditions like high cholesterol levels, smoking, and inactive lifestyles necessitates effective diabetes management.Disease management is essential to prevent complications like kidney failure, gangrene, lower limb amputation, heart attack, blindness, and stroke. Diabetes tracker devices, such as diabetes monitoring software and artificial pancreas systems, help healthcare providers analyze glucose patterns and create treatment plans. User-friendly interfaces, visual representations, and medication adherence features enhance the efficacy of treatment. In summary, diabetes management devices, including insulin delivery devices, continuous monitoring systems, and glucose monitoring devices, are essential tools for managing diabetes and preventing complications. These devices offer precision, flexibility, and smart features, making diabetes care more accessible and convenient for individuals with diabetes. Hospital segment, diagnostic centers, diabetes clinics, and healthcare professionals uti

The global digital diabetes tools market is experiencing robust growth, driven by the rising prevalence of diabetes worldwide, increasing technological advancements, and a growing preference for convenient, self-managed diabetes care. The market, estimated at $15 billion in 2025, is projected to witness a Compound Annual Growth Rate (CAGR) of 12% from 2025 to 2033, reaching approximately $45 billion by 2033. Key drivers include the increasing adoption of continuous glucose monitoring (CGM) systems, the expansion of telehealth services facilitating remote patient monitoring, and the development of sophisticated mobile applications for diabetes management. Market segmentation reveals significant growth across various applications, with the hospital and clinic segments leading the charge due to increased access to advanced technologies and professional support. The home segment is also witnessing rapid expansion, empowered by user-friendly devices and applications enabling self-monitoring and better disease management. Similarly, the medical devices segment holds the largest share, but the virtual tools segment is exhibiting the highest CAGR, reflecting the rising acceptance of digital health solutions. Geographic analysis indicates North America currently holds the largest market share due to high diabetes prevalence and advanced healthcare infrastructure, followed by Europe and Asia Pacific. However, Asia Pacific is expected to show significant growth in the forecast period driven by increasing awareness, rising disposable incomes, and improving healthcare access. The market faces restraints such as high initial costs associated with some technologies, concerns regarding data security and privacy, and the need for improved digital literacy among patients. Leading companies such as Lifescan, Roche, and Medtronic are actively investing in research and development to improve product offerings and expand market reach. The competitive landscape is characterized by both established players and emerging innovative companies. The future of the digital diabetes tools market is promising. Continuous innovation in CGM technology, the integration of artificial intelligence (AI) for personalized diabetes management, and the increasing focus on preventative care are poised to accelerate market growth. Furthermore, the integration of digital diabetes tools into broader healthcare ecosystems and the expanding role of remote patient monitoring are expected to create new opportunities. While challenges remain concerning affordability and data security, ongoing technological advancements and supportive government policies are expected to address these concerns, propelling the market towards a future of enhanced diabetes care and improved patient outcomes. The expanding availability of data-driven insights will be paramount in guiding future development and personalization of these tools.

Objective. Patients with diabetes have higher mortality rate than patients without diabetes after ST-segment elevated myocardial infarction (STEMI). Prognosis of patients with new onset diabetes (NOD) after STEMI remains unclear. The aim of this study was to evaluate the prognosis of patients with NOD compared to that of patients without NOD after STEMI. Design. This study was a retrospective observational study. We enrolled 901 STEMI patients. Patients were divided into diabetic and non-diabetic groups at index admission. Non-diabetic group was divided into NOD and non-NOD groups. Kaplan-Meier analysis and Cox's proportional hazard regression models were used to compare major adverse cardiac events (MACE) free survival rate and hazard ratio for MACE between NOD and non-NOD groups. Results. Mean follow-up period was 59 ± 28 months. Diabetes group had higher MACE than non-diabetes group (p = .038). However, MACE was not different between NOD and non-NOD groups (p = 1.000). After 1:2 propensity score matching, incidence of MACE was not different between the two groups. In Kaplan-Meier survival curves, MACE-free survival rates were not statistically different between NOD and non-NOD groups either (p = .244). Adjusted hazard ratios of NOD for MACE, all-cause of death, recurrent myocardial infarction, and target vessel revascularization were 0.697 (95% confidence interval [CI]: 0.362–1.345, p = .282), 0.625 (95% CI: 0.179–2.183, p = .461), 0.794 (95% CI: 0.223–2.835, p = .723), and 0.506 (95% CI: 0.196–1.303, p = .158), respectively. Conclusion. This retrospective observational study with a limited statistical power did not show a different prognosis in patients with and without NOD.

The global Diabetes Care Intelligence Center market is poised for substantial growth, projected to reach a valuation of approximately USD 45 billion by 2025, with a robust Compound Annual Growth Rate (CAGR) of around 8.5% expected throughout the forecast period extending to 2033. This impressive expansion is primarily driven by the escalating global prevalence of diabetes, a chronic condition affecting millions worldwide. Key factors contributing to this surge include sedentary lifestyles, unhealthy dietary habits, and an aging global population, all of which heighten the risk of developing diabetes. Furthermore, increasing awareness about diabetes management and the availability of advanced diagnostic and monitoring technologies are fueling market demand. The growing emphasis on personalized healthcare and the integration of data analytics and artificial intelligence in diabetes management are also significant accelerators. This intelligence center will play a crucial role in providing actionable insights to stakeholders, enabling more effective diabetes prevention, diagnosis, and treatment strategies. The market is characterized by a dynamic landscape with continuous innovation in diabetes care solutions. Segmentation by Type reveals that "Diabetes Prevalence" is a dominant factor, underscoring the sheer volume of individuals requiring diabetes management. The "Hospital" segment, leveraging advanced technologies and specialized care, is expected to lead in application, while the growing trend of remote patient monitoring and self-management will propel the "Personal" application segment. Major pharmaceutical and medical device companies are heavily investing in research and development, introducing sophisticated blood glucose monitoring systems, insulin delivery devices, and digital health platforms. Restraints, such as the high cost of some advanced technologies and challenges in data standardization, are being addressed through ongoing technological advancements and evolving regulatory frameworks. The market is highly competitive, with established players and emerging startups vying for market share, fostering an environment of rapid innovation and product development.

Snapshot img

Digital Diabetes Management Market Size 2025-2029

The digital diabetes management market size is forecast to increase by USD 16.57 billion, at a CAGR of 13.6% between 2024 and 2029.

The market is witnessing significant growth due to the rising global burden of diabetes. The increasing prevalence of diabetes and the need for effective management solutions have created a substantial demand for digital diabetes management systems. Another key driver is the integration of Artificial Intelligence (AI) in wearable medical devices, enabling real-time monitoring and analysis of patient data, thereby improving diabetes management and outcomes.
Companies must navigate these regulatory hurdles while ensuring the highest standards of data security and patient privacy to capitalize on the market opportunities and provide effective digital diabetes management solutions. However, the market faces challenges from stringent regulatory frameworks in digital diabetes management. Regulatory bodies are emphasizing data security and privacy concerns, which can hinder market growth.

What will be the Size of the Digital Diabetes Management Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

The market continues to evolve, offering innovative solutions for effective diabetes care across various sectors. Diabetes education resources, such as glycemic control algorithms and insulin pump therapy, have revolutionized type 1 diabetes management. The use of technology and digital tools to help people with diabetes track and control their disease is referred to as digital diabetes management. This covers gadgets, including glucometers, insulin pumps, continuous glucose monitoring systems, and mobile software. The oversight of the appropriate use of these technological instruments and the provision of thorough testing services for diabetes management are crucial functions of diagnostic centers. 
. For instance, a leading diabetes telehealth platform reported a 30% increase in patient engagement through remote monitoring and artificial pancreas systems. Lifestyle modification programs and predictive diabetes models further support patients in managing their condition effectively. Wearable sensor technology and continuous glucose monitoring contribute to improved glycemic control and prevent diabetes complications. Industry growth in digital diabetes management is expected to reach 15% annually, fueled by the integration of secure data transmission and health data interoperability.

How is this Digital Diabetes Management Industry segmented?

The digital diabetes management industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

End-user

  Hospitals
  Home settings
  Diagnostic centers


Type

  Wearable devices
  Hand-held devices


Product

  SMBG meters
  Insulin pumps
  CGM devices
  CGM sensors
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    Japan
    South Korea


  South America

    Brazil


  Rest of World (ROW)

By End-user Insights

The Hospitals segment is estimated to witness significant growth during the forecast period. The hospital segment in the global digital diabetes management market refers to the use of digital tools and technologies for the management and treatment of diabetes within a hospital setting. This segment includes various digital solutions such as mobile applications, online platforms, electronic health records (EHRs), medical devices, and telehealth services that are used by healthcare professionals and patients to manage diabetes. The following are some key aspects of the hospital segment in the digital diabetes management market: Remote patient monitoring: Hospitals use technological instruments to remotely check diabetic patients blood glucose levels. Patients can achieve this by using glucose monitoring devices and sending information to medical personnel. It enables continuous monitoring of blood sugar levels, enabling prompt action and individualized treatment advice.

The home settings segment in the global digital diabetes management market refers to the use of digital technologies and devices for managing diabetes in the comfort of an individuals home. It encompasses various digital solutions that enable patients to monitor their blood glucose levels, track their insulin or medication intake, record their diet and exercise, and communicate with healthcare professionals remotely. Some key components of the home-settings segment in digital diabetes management include the following: Blood glucose monitoring tools: Without the necessity for conventional finger-prick testing, these tools enable patients t

Artificial Intelligence in Diabetes Management Market Outlook

The global Artificial Intelligence in Diabetes Management market is projected to witness substantial growth over the forecast period, with the market size estimated to expand from USD 2.3 billion in 2023 to approximately USD 8.7 billion by 2032, reflecting a robust compound annual growth rate (CAGR) of 16.0%. This remarkable growth can be attributed to several factors, including the rising prevalence of diabetes worldwide, the increasing adoption of AI in healthcare, and the continuous advancements in AI technology that promise to enhance patient outcomes and streamline diabetes management practices.

One of the primary growth drivers of this market is the escalating prevalence of diabetes on a global scale. According to the International Diabetes Federation, diabetes affects over 537 million adults worldwide, and this number is projected to rise alarmingly over the coming years. This growing epidemic is fueling the demand for innovative and efficient management tools, with AI-based solutions emerging as a frontrunner in addressing these needs. AI technologies offer enhanced capabilities in monitoring glucose levels, predicting fluctuations, and personalizing treatment plans, thus improving patient compliance and outcomes. Moreover, the increasing awareness among patients and healthcare providers about the benefits of AI in managing chronic conditions further bolsters market growth.

The rapid technological advancements in artificial intelligence, particularly in machine learning and data analytics, are another significant factor propelling the market forward. These technologies enable the development of sophisticated algorithms capable of processing vast amounts of healthcare data to generate actionable insights. In diabetes management, this translates to more accurate glucose monitoring, predictive analytics for insulin delivery, and personalized patient management strategies. The ongoing research and development in AI technologies are expected to introduce future innovations that will further enhance the efficiency and efficacy of diabetes management solutions, thereby expanding the market's potential.

Additionally, the increasing integration of AI with existing healthcare infrastructure is transforming the diabetes management landscape. The collaboration between AI and traditional healthcare systems facilitates seamless data exchange, leading to more comprehensive patient profiles and informed decision-making. This integration also supports the shift towards value-based care, emphasizing improved patient outcomes and cost efficiency. Moreover, government initiatives and favorable reimbursement policies for AI-driven healthcare solutions are encouraging healthcare providers to adopt these technologies, creating lucrative opportunities for market growth.

From a regional perspective, North America currently holds the largest share in the AI in diabetes management market, driven by the high prevalence of diabetes, advanced healthcare infrastructure, and significant investments in AI research and development. However, Asia Pacific is anticipated to witness the highest growth rate over the forecast period, supported by the increasing incidence of diabetes, growing healthcare expenditure, and the rapid adoption of digital health technologies in emerging economies. Europe also presents a promising market, with a strong focus on the integration of AI in healthcare systems and favorable regulatory environments. Together, these regions contribute to the dynamic and widespread expansion of the AI in diabetes management market globally.

Component Analysis

The component analysis of the Artificial Intelligence in Diabetes Management market reveals that the software segment holds a dominant position. This segment includes AI algorithms and platforms that facilitate glucose monitoring, insulin delivery, predictive analytics, and patient management. These software solutions are integral to the successful implementation of AI in diabetes management, as they process and interpret vast data sets to generate actionable insights. The continuous evolution of AI algorithms, focusing on improving accuracy and efficiency, is driving the growth of the software segment. Additionally, the increasing demand for personalized diabetes management solutions is further fueling the adoption of AI-powered software, as it offers customizable features tailored to individual patient needs.

Hardware components, although a smaller segment compared to software, play a crucial role in the AI diabetes management ecosystem. This segment encom

Diabetes Care or Diabetic care market Size to reach USD 113.2 Billion by 2034 at a CAGR of 7.3%. Diabetic care Classifies Global Market By Devices, Distribution Channel, End User and Region | Diabetes Treatment Market | Diabetes Management Market | Diabetic Care Industry

The Philippines diabetes testing market, specifically focusing on trister test strips, presents a compelling growth opportunity. While precise figures for the trister test strip segment within the broader ₱77.63 million (assuming this is in Philippine Pesos) blood glucose monitoring market are unavailable, we can project its trajectory based on established market trends. Considering the high prevalence of diabetes in the Philippines and increasing awareness of self-management, the demand for trister test strips (a component of self-monitoring blood glucose devices) is likely substantial and growing. The 7.20% CAGR across the entire blood glucose monitoring market suggests a healthy expansion for all related segments, including trister test strips. Drivers include rising diabetes incidence, an aging population requiring more frequent testing, and increasing affordability of home-testing devices. Furthermore, the growing adoption of continuous glucose monitoring (CGM) systems might indirectly impact trister test strip usage, but the substantial number of individuals relying on self-monitoring blood glucose (SMBG) devices will likely ensure continued demand. Potential restraints could include limited healthcare access in certain regions, inconsistent insurance coverage for diabetes supplies, and the emergence of alternative testing technologies. However, the overall outlook remains positive, driven by the increasing need for effective diabetes management within the Philippine population. Further market segmentation within trister test strips themselves could reveal significant insights. For instance, analyzing the market based on the type of glucometer devices compatible with specific test strips, or differentiating between premium and budget options, could yield more granular understandings of market segments and their respective growth rates. Competitive analysis across key players like Becton Dickinson, Medtronic, and Abbott, each with various offerings within the trister test strip market, would also enhance our understanding of the competitive landscape. This segment-specific market analysis will require additional research to yield precise, quantifiable data. However, the existing data points towards a significant and expanding market within the Philippines. Recent developments include: March 2024: Novo Nordisk Philippines collaborated with Roche Diabetes Care and Humanity and Inclusion to launch the Changing Diabetes in Children (CDiC) program in Valenzuela City, Philippines. This five-year program aims to provide comprehensive patient education, bolster the healthcare workforce, establish a network of clinic facilities, and ensure free access to insulin and medical supplies for children and young adults with type 1 diabetes., September 2023: The Department of Health (DOH) cautioned people in the Philippines regarding misleading information about diabetes remedies as a part of the diabetes awareness program. The Department of Health (DOH) stressed that adopting a healthy lifestyle was key to preventing non-communicable diseases, such as diabetes, rather than depending on products sold online.. Key drivers for this market are: Rising Diabetes Prevalence in the Country, Growing Government Initiatives to Boost Adoption of Diabetes Care Devices. Potential restraints include: Rising Diabetes Prevalence in the Country, Growing Government Initiatives to Boost Adoption of Diabetes Care Devices. Notable trends are: The Increasing Diabetes Population in the Philippines is Expected to Drive the Market During the Forecast Period.

The global glucose tracking app market is experiencing robust growth, driven by the rising prevalence of diabetes and the increasing adoption of digital health solutions. The market, valued at approximately $1.5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2033. This significant growth is fueled by several key factors. Firstly, the increasing awareness of diabetes management and the need for proactive monitoring among individuals with diabetes and prediabetes is driving demand. Secondly, the convenience and accessibility offered by these apps, allowing for remote monitoring and data sharing with healthcare providers, are proving highly attractive. Thirdly, technological advancements are continually enhancing app functionality, incorporating features like medication reminders, meal tracking, and integration with continuous glucose monitors (CGMs). The segment comprising cloud-based apps holds a dominant market share due to its flexibility and accessibility, while the personal application segment is larger than the family application segment reflecting the individual nature of diabetes management. However, challenges remain. Data privacy concerns and the need for regulatory compliance are potential restraints. Furthermore, ensuring app accuracy and reliability is crucial for user trust and adoption. Competition among existing players and the entry of new entrants are also shaping the market landscape. Future growth will likely be influenced by advancements in AI-driven analytics within the apps, personalized diabetes management programs, and greater integration with wearable devices. Geographical expansion, particularly in developing countries with high diabetes prevalence, presents significant opportunities. The market is segmented by type (cloud-based, on-premises) and application (personal, family), with significant regional variations across North America, Europe, Asia-Pacific, and other regions reflecting varying levels of technological adoption and healthcare infrastructure.

The European diabetic care devices market, valued at €8.03 billion in 2025, is projected to experience robust growth, driven by rising prevalence of diabetes, an aging population, and increasing awareness of effective disease management. A compound annual growth rate (CAGR) of 6.18% from 2025 to 2033 indicates a significant expansion in market size, reaching an estimated €13.2 billion by 2033. Key growth drivers include technological advancements in continuous glucose monitoring (CGM) systems, offering improved convenience and accuracy compared to traditional self-monitoring blood glucose (SMBG) methods. The increasing adoption of insulin pumps and sophisticated insulin delivery systems further contributes to market expansion. While the market faces restraints like high device costs and the need for continuous patient education, the overall positive trend is fueled by supportive government initiatives and a growing focus on proactive diabetes management, including remote monitoring and telehealth solutions. The market segmentation reveals significant opportunities within CGM, which is projected to outpace SMBG growth due to its enhanced patient experience and improved glycemic control. This is particularly relevant given the increasing prevalence of type 1 diabetes and the associated need for intensive glucose management among younger populations. The competitive landscape is dominated by established players like Dexcom, Medtronic, and Abbott, with a focus on innovation, product differentiation, and strategic partnerships to expand market reach and address unmet needs within specific patient segments. Smaller companies are also actively contributing, driving innovation in areas such as sensor technology and data analytics for personalized diabetes management. Regional variations within Europe exist due to differing healthcare systems, reimbursement policies, and prevalence rates of diabetes. Countries like Germany and the UK are expected to contribute significantly to the overall market growth owing to their large populations and relatively robust healthcare infrastructures. The increasing focus on value-based care and cost-effectiveness in healthcare systems across Europe will also influence the choice of devices and treatment strategies, driving further market segmentation and impacting future growth projections. Recent developments include: Feburary 2024: Dexcom launched real-time CGM solution Dexcom ONE+ in Europe. Dexcom ONE+ is a customisable continuous glucose monitoring solution that can be worn at three different location on the body., June 2022: Cequr, the leader in wearable diabetes technology, released its newest and most innovative insulin delivery device, the Insulin Pen 2.0TM. The pen is small enough to be always worn on the user's body, and it also features a built-in blood glucose meter so that users can track their blood sugar throughout the day.. Notable trends are: The continuous glucose monitoring segment is expected to witness the highest growth rate over the forecast period.

Digital Diabetes Prevention Programs Market Outlook

According to our latest research, the global Digital Diabetes Prevention Programs (DPP) market size reached USD 1.62 billion in 2024. The market is experiencing robust growth, with a recorded CAGR of 19.8% from 2025 to 2033. By the end of 2033, the market is projected to reach USD 7.93 billion. This surge is primarily driven by the increasing prevalence of prediabetes and type 2 diabetes worldwide, coupled with the growing adoption of digital health solutions that offer scalable, personalized, and data-driven approaches to diabetes prevention. As per our latest research, the digital diabetes prevention ecosystem is witnessing significant investment, technological advancements, and integration with broader digital health platforms, making it a pivotal segment in the global healthcare industry.

One of the primary growth factors fueling the expansion of the Digital Diabetes Prevention Programs market is the escalating global burden of diabetes and prediabetes. According to the International Diabetes Federation, over 540 million adults were living with diabetes in 2024, with millions more at risk due to prediabetes. This alarming trend has prompted healthcare systems, employers, and insurers to seek innovative, cost-effective solutions for risk reduction and early intervention. Digital DPPs leverage evidence-based curricula, behavioral science, and remote monitoring to deliver personalized interventions at scale. The convenience of accessing these programs through digital platforms—be it web-based portals, mobile applications, or telehealth—has significantly improved patient engagement and adherence, leading to better clinical outcomes and reduced healthcare costs.

Another critical driver of market growth is the rapid advancement and integration of technology within digital diabetes prevention solutions. Artificial intelligence, machine learning, and data analytics are being harnessed to deliver real-time feedback, adaptive coaching, and predictive risk assessments. These technologies enable continuous monitoring of user progress and allow for tailored interventions that address individual needs. Furthermore, the interoperability of digital DPPs with electronic health records (EHRs), wearable devices, and other digital health tools enhances the overall value proposition for healthcare providers and payers. The ability to seamlessly integrate digital DPPs into existing care pathways not only improves population health management but also supports value-based care initiatives by demonstrating measurable improvements in health outcomes.

The supportive regulatory landscape and increasing reimbursement opportunities are also contributing to the market’s upward trajectory. In several regions, including the United States and parts of Europe, digital DPPs have gained recognition from health authorities and insurance providers, paving the way for broader adoption. For instance, the US Centers for Medicare & Medicaid Services (CMS) has included digital DPPs in its reimbursement framework, encouraging both providers and patients to participate in these preventive programs. The COVID-19 pandemic has further accelerated the shift towards digital health, highlighting the importance of remote care and chronic disease prevention. As a result, stakeholders across the healthcare ecosystem—ranging from individuals to large employers and payers—are increasingly investing in digital DPPs as a strategic tool to curb the diabetes epidemic.

From a regional perspective, North America currently dominates the Digital Diabetes Prevention Programs market, accounting for the largest share in 2024, followed closely by Europe and the Asia Pacific. The high prevalence of diabetes, advanced digital infrastructure, and proactive healthcare policies in North America have created a fertile ground for digital DPP adoption. Europe is witnessing significant growth due to increasing government initiatives and rising awareness about preventive healthcare. Meanwhile, the Asia Pacific region is emerging as a high-growth market, driven by a surge in smartphone penetration, expanding internet access, and a growing middle class that is increasingly health-conscious. Latin America and the Middle East & Africa are also showing promising potential, albeit from a smaller base, as healthcare systems in these regions begin to embrace digital transformation and preventive care.

<div class="free_sample_div text-center

The Continuous Glucose Monitoring (CGM) market is experiencing robust growth, projected to reach $11.63 billion in 2025 and expand significantly over the forecast period (2025-2033). A compound annual growth rate (CAGR) of 12.89% reflects the increasing prevalence of diabetes, advancements in CGM technology (such as smaller, less invasive sensors and improved accuracy), and rising patient preference for convenient, real-time glucose monitoring. Key drivers include the rising incidence of type 1 and type 2 diabetes globally, increasing healthcare expenditure, and growing awareness among patients about the benefits of proactive diabetes management. Technological advancements are leading to the development of more user-friendly and accurate CGMs, further fueling market expansion. The market is segmented by component (sensors, durables like receivers and transmitters) and end-user (hospitals/clinics, home/personal use). Hospitals and clinics currently represent a larger segment, but the home/personal use segment is rapidly growing due to increasing affordability and convenience of at-home monitoring. Major players like Abbott, Dexcom, and Medtronic are driving innovation and market penetration through continuous product development and strategic partnerships. While some restraints exist, such as high initial costs and potential skin irritation from sensors, these are being addressed through ongoing technological advancements and innovative business models that make CGM more accessible. Geographic growth is expected across all regions, with North America and Europe currently leading the market, driven by high diabetes prevalence and advanced healthcare infrastructure. However, Asia Pacific is anticipated to show significant growth potential in the coming years due to increasing diabetes rates and rising disposable incomes. The future of the CGM market appears exceptionally bright. The ongoing development of hybrid closed-loop systems, which automatically adjust insulin delivery based on CGM data, represents a significant leap forward in diabetes management and will undoubtedly stimulate further market expansion. The integration of CGM data with mobile applications and cloud-based platforms enhances data accessibility and empowers patients to actively participate in their healthcare management. Furthermore, the development of minimally invasive and implantable sensors promises to increase patient comfort and improve long-term usability, further driving market penetration and creating new growth opportunities. Competitive landscape analysis reveals that strategic acquisitions, partnerships, and the introduction of innovative products will continue to shape the market dynamics in the coming years. Key drivers for this market are: Rising Prevalence of Diabetes Fostering Research and Treatment, Government Support initiatives to Construct the Spread of Diabetes. Potential restraints include: Rising Prevalence of Diabetes Fostering Research and Treatment, Government Support initiatives to Construct the Spread of Diabetes.

The Diabetes Care Drugs market is a vital segment of the global healthcare industry, dedicated to managing and treating diabetes, a chronic metabolic condition characterized by high blood sugar levels. As millions of individuals worldwide grapple with this condition, the demand for effective diabetes medications con

The Type 1 Diabetes (T1D) market is a critical segment within the global diabetes care landscape, primarily focusing on the management and treatment of a condition that affects millions worldwide. Characterized by the body's inability to produce insulin, T1D is typically diagnosed in children and young adults, neces

The Italian diabetes care devices market, valued at €1.03 billion in 2025, is projected to experience robust growth, driven by a rising prevalence of diabetes, an aging population, and increasing awareness of advanced diabetes management technologies. The market's Compound Annual Growth Rate (CAGR) of 6.70% from 2025 to 2033 signifies substantial expansion opportunities. Key drivers include the increasing adoption of continuous glucose monitoring (CGM) systems, offering real-time glucose data for better glycemic control, and the growing preference for insulin pumps over traditional injection methods. These trends are fueled by technological advancements leading to smaller, more user-friendly devices with improved accuracy and features. While market penetration of these advanced technologies remains relatively lower compared to other European nations, the Italian market is poised for significant uptake due to increased healthcare expenditure and government initiatives supporting diabetes management. However, factors like high device costs and limited insurance coverage for certain advanced technologies, coupled with potential supply chain disruptions, present constraints to market growth. Segment-wise, the self-monitoring blood glucose (SMBG) segment, encompassing glucometers, test strips, and lancets, currently holds a significant share, while the CGM segment is experiencing rapid growth, expected to capture a larger market share in the coming years. Within the insulin delivery devices segment, insulin pumps are showing a steady increase in demand driven by improved convenience and efficacy. The competitive landscape is dominated by major players like Abbott, Roche, LifeScan, Dexcom, and Medtronic, with smaller companies and regional players contributing to the market's overall dynamism. Market strategies focusing on innovative device features, improved patient access, and strategic collaborations with healthcare providers are crucial for success in this expanding market. Growth opportunities exist in expanding access to CGM across various age groups and diabetes types. Recent developments include: June 2022: Cequr, the leader in wearable diabetes technology, released their newest and most innovative insulin delivery device yet, the Insulin Pen 2.0TM. The pen is small enough to be always worn on the user's body. It also features a built-in blood glucose meter so users can track their blood sugar throughout the day., January 2022: Roche launched its new point-of-care blood glucose monitor designed for hospital professionals, with a companion device shaped like a touchscreen smartphone that will run its apps. The hand-held Cobas pulse includes an automated glucose test strip reader, a camera, and a touchscreen for logging other diagnostic results. It's designed for patients of all ages, including neonates and people in intensive care.. Notable trends are: The continuous glucose monitoring segment is expected to witness the highest growth rate over the forecast period.

The global glucose analyzer market is experiencing robust growth, driven by the rising prevalence of diabetes and related conditions worldwide. The increasing geriatric population, coupled with the growing adoption of self-monitoring blood glucose (SMBG) techniques, significantly fuels market expansion. Technological advancements, such as the development of continuous glucose monitoring (CGM) systems offering real-time glucose data, are revolutionizing diabetes management and contributing to market growth. Furthermore, the increasing demand for accurate and reliable glucose monitoring devices, especially in developing economies with burgeoning diabetic populations, is a key driver. Competitive landscape analysis reveals several key players like Johnson & Johnson, Abbott, Roche, and Medtronic leading the market with innovative products and a strong global presence. These companies are focusing on product differentiation through advanced features, improved accuracy, and user-friendly interfaces to cater to evolving patient needs. While regulatory approvals and pricing pressures pose certain challenges, the overall market outlook remains highly positive, projecting substantial growth throughout the forecast period. Despite the significant market potential, the glucose analyzer market faces some restraints. These include the high cost of advanced technologies like CGM, particularly in lower-income regions, limiting accessibility for a large population segment. Furthermore, the market is subject to stringent regulatory frameworks governing the development and approval of medical devices, resulting in potentially lengthy time-to-market for new products. However, the ongoing research and development efforts focused on improving the accuracy, affordability, and usability of glucose analyzers are mitigating these challenges to some extent. The segment comprising CGM systems is expected to exhibit the fastest growth rate due to the convenience and real-time data provided, while the traditional SMBG segment continues to maintain a significant market share due to its affordability and accessibility. Regional variations in market growth reflect varying levels of healthcare infrastructure and diabetes prevalence across different geographical locations.

The global diabetes care devices market is expected to reach USD 64.5 billion in 2024. The sales are expected to grow even higher and will be estimated at USD 117.7 billion in 2034 due to the rising diabetes population. The diabetes care devices market is anticipated to record a CAGR of 6.2% between 2024 and 2034.

Attributes	Description
Estimated Global Diabetes Care Devices Market Size (2024E)	USD 64.5 billion
Projected Global Diabetes Care Devices Market Value (2034F)	USD 117.7 billion
Value-based CAGR (2024 to 2034)	6.2%

Semi-annual Industry Update

Particular	Value CAGR
H1	5.7% (2023 to 2033)
H2	5.2% (2023 to 2033)
H1	4.5% (2024 to 2034)
H2	4.2% (2024 to 2034)

Country-wise Insights

Countries	CAGR 2024 to 2034
India	8.8%
China	8.4%
South Korea	8.1%
Australia	6.7%
France	4.3%
United States	3.4%

Category-wise Insights

Segment	Glucose Monitoring Devices (Product Type)
Value Share (2024)	58.3%

Segment	Diabetes Type II (Indication)
Value Share (2024)	19.7%